Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...But in March, as the pandemic hit hospital wards around Pfizer’s Manhattan headquarters, the two companies announced a collaboration....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Dr Fischer and other experts may be trying to be transparent so as to build confidence, according to sociologist Jeremy Ward....
...programme on Sunday morning with elderly patients and medical staff in Sevran near Paris — the first to receive the injection was Mauricette, a 78-year-old retired cleaning lady — to be followed by a geriatric ward...
...From a young age, she would follow him as he did his rounds through the wards of his hospital in Lower Saxony, and even into the operating theatre....
...(Citywire, 43m) Yemen’s ‘hunger wards’ Already home to the world’s worst humanitarian crisis, Yemen is now suffering from acute famine....
...Chantelle Cseh Partner, Davies Ward Phillips & Vineberg As an associate in 2015, Chantelle Cseh designed a model to conduct a paperless trial for the Husky Injection Molding Systems v Robert Schad litigation...
...“As a councillor in a ward that suffers from areas of multiple deprivation — where poverty affects one in three children — I cannot indulge,” Mr Malone wrote....
...It gave the job to Pfizer, the US pharmaceutical company, which it seems messed it up....
...Pfizer, which sold the Hospira Infusion business to ICU Medical in February 2017, said it was co-ordinating with the new owner to “produce records for the DoJ”....
...“We are at the beginning of the immuno-oncology era and only starting to understand the complexities of the tumour ecosystem,” says Chris Boshoff, head of early development in immuno-oncology for Pfizer....
...Now Pfizer must show it has a future without its erstwhile partner....
...“It is early days,” says Chris Boshoff, who directs early development of cancer immunotherapies at Pfizer....
..., as Pfizer has done with Prevnar....
...Weak health infrastructure in many parts of the developing world is a problem and many health activists blame manufacturers such as Pfizer and GlaxoSmithKline for pricing their drugs too high....
...Pfizer is betting that the “allogeneic” technology pursued by Cellectis will prevail in the long run....
...There has been speculation about potential rival bidders, such as Pfizer or AstraZeneca, but none have yet entered the fray....
...In the Wyeth case, this would be shared with another whistleblower, Lauren Kieff, a former sales representative for AstraZeneca, a rival of Pfizer’s....
...In March 2015, he fought off stiff competition from Johnson & Johnson and Pfizer to acquire Pharmacyclics, the maker of a blockbuster drug for blood cancers, for $21bn....
...It was not only the corporate tax rate itself — the highest in the developed world — to which Pfizer objected but also its scope....
...Pfizer subsequently turned its attention to other targets and agreed a $160bn deal with Allergan last year....
...Nice, which acts as a gatekeeper for medicines seeking access to the NHS, on Tuesday recommended Inflectra, a biosimilar made by Pfizer, and Remsima, marketed by Napp Pharmaceuticals, as well as Remicade...
International Edition